Loading
A phase 1/2 trial of QLC5508 in advanced solid tumours, run by Qilu Pharmaceutical Co., Ltd., now recruiting.
Study of MHB088C for Patients With Advanced Solid Malignant Tumors is a phase 1/2 interventional study registered as NCT07102004 by Qilu Pharmaceutical Co., Ltd., with 515 participants planned, started 2023-06-20 and due to reach its primary completion in 2026-07. Interventions recorded: MHB088C for Injection.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Qilu Pharmaceutical, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares QLC5508, Qilu Pharmaceutical, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Qilu Pharmaceutical, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Qilu Pharmaceutical, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares QLC5508, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Qilu Pharmaceutical and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/